Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.14Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed multiple operational and clinical positives: solid PEMGARDA commercial growth (31% QoQ, 25% YoY), durable reorder behavior (77%), a strong year-end cash balance ($226.7M after >$200M raised), Declaration enrollment reaching target, favorable IDMC safety recommendations, and an expanding pipeline (RSV, measles, long COVID). Offsetting items were uncertainties tied to external COVID attack rates that could trigger a ~30% trial upsizing and timing risk to the mid‑2026 readout, limited power to detect rare safety events in small studies (e.g., myocarditis in LIBERTY), and early-stage competition/validation needs for RSV and measles programs. On balance, the positive commercial traction, capitalization, enrollment milestone, and favorable early safety signals outweigh the operational and timing risks.Company Guidance
PEMGARDA Revenue Growth
PEMGARDA net revenues grew 31% quarter-over-quarter in Q4 2025 and 25% year-over-year versus Q4 2024; full-year 2025 net revenues totaled $53.4 million.
Strong Cash Position and Fundraising
Raised over $200 million in 2025 and ended the year with $226.7 million in cash and cash equivalents, positioned to fund pivotal VYD2311 data in mid-2026 (and potentially beyond subject to commercial performance and operational discipline).
Commercial Traction and Durable Demand
High commercial engagement: 77% account reorder rate for PEMGARDA and more than 15,000 contracted GPO sites, with expanding adoption across hematology, oncology, rheumatology, infectious disease, transplant, neurology and other specialties.
Declaration Trial Enrollment Milestone
Declaration randomized, triple-blind study reached target enrollment (~1,770 subjects randomized 1:1:1:1) and has begun accruing COVID events, with event accumulation described as 'on track' to support assessment of VYD2311 effectiveness.
Positive Safety/Tolerability IDMC Recommendations
Independent Data Monitoring Committee recommended easing enrollment restrictions: pregnant and breastfeeding women may enroll, contraception no longer required for women of childbearing age, and several prespecified early post-dose safety visits (days 8, 38, 68) are no longer required — indicating a favorable initial safety/tolerability profile.
VYD2311 Profile and Clinical Strategy
VYD2311 characterized as more potent in vitro than pemivibart with a longer measured half-life and formulated for intramuscular dosing; Invivyd is running its third randomized, placebo-controlled COVID monoclonal antibody trial and anticipates mid-year (Q2–Q3 2026) pivotal data timing if upsizing is not required.
Pipeline Expansion and Targeted Indications
Pipeline broadened beyond COVID: beginning clinical exploration in long COVID and post-vaccine syndrome, identified a highly potent RSV antibody (positioned as competitive with existing standard of care), and expects an update on the measles program in H1 2026 — signaling diversified infectious-disease R&D.
Regulatory and Guideline Momentum
Increased clinical recognition for monoclonal antibody prophylaxis: PEMGARDA included in NCCN guidelines for B-cell lymphomas; ACIP scheduled discussions on long COVID/post-vaccine syndrome which could influence future receptivity to antibody approaches.
IVVD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IVVD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $1.52 | $1.54 | +1.32% |
Aug 14, 2025 | $0.80 | $0.71 | -11.25% |
May 15, 2025 | $0.84 | $0.70 | -16.67% |
Mar 20, 2025 | $0.72 | $0.74 | +2.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Invivyd (IVVD) report earnings?
Invivyd (IVVD) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Invivyd (IVVD) earnings time?
Invivyd (IVVD) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IVVD EPS forecast?
IVVD EPS forecast for the fiscal quarter 2026 (Q1) is -0.02.